Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fujisaka

Showing results (181-190 of 253) with videos related to

Pageof 26
Sort By:
Anticancer Research|October 1, 2021
Comparison Between Second- and Third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as First-line Treatment in Patients With Non-small-cell Lung Cancer: A Retrospective AnalysisSho Mitsuya, Kenjiro Tsuruoka, Kiyoe Kanaoka, et al.
Nucleic Acid Therapeutics|January 20, 2021
Considerations of the Japanese Research Working Group for the ICH S6 & Related Issues Regarding Nonclinical Safety Assessments of Oligonucleotide Therapeutics: Comparison with Those of BiopharmaceuticalsYoko Hirabayashi, Kazushige Maki, Kiyoshi Kinoshita, et al.
Cancer Chemotherapy and Pharmacology|January 31, 2014
An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumorsH Murakami, T Kurata, Y Onozawa, et al.
Cancer Science|October 2, 2012
Phase I trial of OTS11101, an anti-angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumorHidetoshi Hayashi, Takayasu Kurata, Yasuhito Fujisaka, et al.
JTO Clinical and Research Reports|February 7, 2024
Severe Drug-Induced Interstitial Lung Disease After Administration of Osimertinib as Adjuvant Treatment for Resected EGFR-Mutated NSCLC: A Case ReportSho Mitsuya, Masahiro Arai, Kiyoe Kanaoka, et al.
The Tohoku Journal of Experimental Medicine|November 13, 2015
Radiation Therapy Is a Reasonable Option for Improving the Prognosis in Hepatocellular CarcinomaYasuteru Kondo, Osamu Kimura, Takayuki Kogure, et al.
Cell Reports|March 15, 2018
Diet, Genetics, and the Gut Microbiome Drive Dynamic Changes in Plasma MetabolitesShiho Fujisaka, Julian Avila-Pacheco, Marion Soto, et al.
The Tohoku Journal of Experimental Medicine|January 5, 2017
Identification of Genotype 2 HCV in Serotype-1 Hepatitis C Patients Unresponsive to Daclatasvir plus Asunaprevir TreatmentJun Inoue, Atsushi Kanno, Yuta Wakui, et al.
Iscience|May 17, 2021
Gut microbiota, determined by dietary nutrients, drive modification of the plasma lipid profile and insulin resistanceYoshiyuki Watanabe, Shiho Fujisaka, Kazutaka Ikeda, et al.
Endocrinology|March 24, 2007
Chronic tumor necrosis factor-alpha treatment causes insulin resistance via insulin receptor substrate-1 serine phosphorylation and suppressor of cytokine signaling-3 induction in 3T3-L1 adipocytesKen Ishizuka, Isao Usui, Yukiko Kanatani, et al.
Pageof 26

Showing results (181-190 of 253) with videos related to

Sort By:
Pageof 26
Anticancer Research|October 1, 2021
Comparison Between Second- and Third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as First-line Treatment in Patients With Non-small-cell Lung Cancer: A Retrospective AnalysisSho Mitsuya, Kenjiro Tsuruoka, Kiyoe Kanaoka, et al.
Nucleic Acid Therapeutics|January 20, 2021
Considerations of the Japanese Research Working Group for the ICH S6 & Related Issues Regarding Nonclinical Safety Assessments of Oligonucleotide Therapeutics: Comparison with Those of BiopharmaceuticalsYoko Hirabayashi, Kazushige Maki, Kiyoshi Kinoshita, et al.
Cancer Chemotherapy and Pharmacology|January 31, 2014
An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumorsH Murakami, T Kurata, Y Onozawa, et al.
Cancer Science|October 2, 2012
Phase I trial of OTS11101, an anti-angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumorHidetoshi Hayashi, Takayasu Kurata, Yasuhito Fujisaka, et al.
JTO Clinical and Research Reports|February 7, 2024
Severe Drug-Induced Interstitial Lung Disease After Administration of Osimertinib as Adjuvant Treatment for Resected EGFR-Mutated NSCLC: A Case ReportSho Mitsuya, Masahiro Arai, Kiyoe Kanaoka, et al.
The Tohoku Journal of Experimental Medicine|November 13, 2015
Radiation Therapy Is a Reasonable Option for Improving the Prognosis in Hepatocellular CarcinomaYasuteru Kondo, Osamu Kimura, Takayuki Kogure, et al.
Cell Reports|March 15, 2018
Diet, Genetics, and the Gut Microbiome Drive Dynamic Changes in Plasma MetabolitesShiho Fujisaka, Julian Avila-Pacheco, Marion Soto, et al.
The Tohoku Journal of Experimental Medicine|January 5, 2017
Identification of Genotype 2 HCV in Serotype-1 Hepatitis C Patients Unresponsive to Daclatasvir plus Asunaprevir TreatmentJun Inoue, Atsushi Kanno, Yuta Wakui, et al.
Iscience|May 17, 2021
Gut microbiota, determined by dietary nutrients, drive modification of the plasma lipid profile and insulin resistanceYoshiyuki Watanabe, Shiho Fujisaka, Kazutaka Ikeda, et al.
Endocrinology|March 24, 2007
Chronic tumor necrosis factor-alpha treatment causes insulin resistance via insulin receptor substrate-1 serine phosphorylation and suppressor of cytokine signaling-3 induction in 3T3-L1 adipocytesKen Ishizuka, Isao Usui, Yukiko Kanatani, et al.
Pageof 26